Kyverna Therapeutics, Inc.
- KYTX
- NASDAQ
- Biotechnology
- CAR T-Cell Therapy
- Autoimmune Disease Treatment
- Cell Therapy
$5.67
Today −5.03%Quote Oct 16, 2026, 08:00 PM UTC
−19.46%over the last month
Max drawdown −24.5%From 1-month high −24.5%3 months −21.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$350.7M
Quote Oct 16
Next earnings
Nov 11
Expected, not confirmed
Analyst target
$25.00
+340.9% from here
Floor
$5.64
0.5% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KYTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
149
Founded
2018